The cloud-based personalized medicine software company will stay in Cambridge, Massachusetts and will become a wholly-owned subsidiary of the institute.
Under the agreement, researchers can use Foundation Medicine's assays to select patients eligible for Sarah Cannon Research Institute's clinical studies.
Researchers presented data suggesting that pharma companies are using basket studies to identify molecularly defined patient subsets who might benefit from their drugs.
The partners will explore the use of Biocept's liquid biopsy technology to identify and detect biomarkers in ER-positive breast cancer patients.
CHICAGO (GenomeWeb) – Research presented at the annual meeting of the American Society of Clinical Oncology this week included a wealth of data from programs using next-generation sequencing to guide treatment for cancer patients.
This article has been updated with additional information from Sarah Cannon Research Institute.Originally published July 2.
NEW YORK (GenomeWeb News) – Sarah Cannon Research Institute and AstraZeneca said today that they will work together to advance drugs in AstraZeneca's pipeline with a personalized medicine strategy.
UCL-Advanced Diagnostics, diagnostic service provider of the University College London Cancer Institute, has opened a new molecular profiling laboratory that will offer a sequencing-based multi-gene test for cancer patients in the UK and elsewhere.